Zydus Lifesciences (formerly Cadila Healthcare) Latest Updates

Major USFDA Approvals In April 2026, Zydus received a landmark final approval from the USFDA for Dapagliflozin Tablets (5 mg and 10 mg), a generic version of the blockbuster diabetes drug Farxiga. This approval is particularly significant as Zydus is eligible for 180 days of shared market exclusivity. The market for this medication in the U.S. is estimated to be over $10 billion annually. Earlier in March 2026, the company also secured approval for Cevimeline Hydrochloride Capsules. Strategic Product Launches & Pipeline The company is aggressively expanding its specialty portfolio, recently launching BEIZRAY (an oncology product) and receiving approval for Zycubo® for the treatment of Menkes disease. Furthermore, Zydus is preparing for a "first wave" launch of a generic Semaglutide (GLP-1) injection in a reusable pen form following patent expiry. For FY27, management has a robust pipeline of 40–45 product launches planned for the U.S. market. Segment-Wise Growth The India Formulations business grew by 14% YoY, driven by chronic therapies which now contribute over 45% of its domestic revenue. The Consumer Wellness segment saw an exceptional 113% YoY growth to ₹960 crore, primarily fueled by the full integration of the Comfort Click acquisition. International markets, including Europe and emerging economies, recorded a 38% revenue jump, and management expects this 20%+ growth trajectory to continue. Supply Chain and Regulatory Outlook MD Sharvil Patel recently highlighted emerging global challenges in the pharmaceutical supply chain, specifically regarding raw materials and logistical constraints. On the regulatory front, the company received a favorable order from the GST department in April 2026, which dropped a pending tax demand of ₹41.77 million from previous years. All major manufacturing facilities recently inspected by the USFDA have maintained positive compliance reports.